TB-500 vs Thymosin Beta-4: Why the Names Cannot Be Used Interchangeably

Thymosin beta-4 has a defined sequence

Thymosin beta-4 is an endogenous 43-amino-acid peptide known for binding monomeric actin. It has been studied in cytoskeletal organization, cell migration, angiogenesis, inflammation, and wound-related models.

TB-500 may not describe the same molecule

TB-500 is used commercially for materials described as thymosin beta-4, fragments, or related synthetic products. Without an exact sequence, molecular mass, termini, counterion, and analytical confirmation, the name does not establish chemical identity.

Fragments can behave differently

A fragment may retain one motif while losing other structural or functional features. Pharmacokinetics, receptor interactions, proteolysis, and tissue distribution may differ materially from the full-length peptide.

Blends multiply the uncertainty

When TB-500-labeled material is combined with BPC-157, GHK-Cu, or other compounds, component identity and quantitative assays become even more important. Blend-level stability and interactions must be studied directly.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.